Company ProfilePremium

Oakridge International Limited

Company Profile Analysis

Ticker: OAK.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Oakridge International Limited - Company showcase

Year Founded & Workforce

2006

Oakridge International Limited logo

Oakridge International Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Oakridge International Limited Overview

Oakridge International is an Australian micro-cap healthcare-technology company. In practice it is the listed holding company for JCT Healthcare Pty Ltd, an Adelaide-based designer, supplier, installer and maintainer of IP nurse call systems, assistive technology, real-time location systems (RTLS) and related software. JCT has operated for more than two decades. Its customers are hospitals, residential aged care, disability care, dementia care and supported independent living (SIL) providers, mainly in Australia. The listed entity has had several lives: a geothermal developer in Indonesia and India, then an IoT platform company (Xped), then a consolidated healthcare-technology business. In FY2026 it recorded revenue and other income of $3.45 million and its first statutory profit since FY2021 ($109,171). However, that profit depends on R&D tax incentives. With a market value near A$2 million, majority control by its CEO and a three-person board, Oakridge is an illiquid, founder-style turnaround story in a market where well-capitalised consolidators are active.


The company's own description

The FY2026 Annual Financial Report says the Group sells professional healthcare-technology equipment and solutions to healthcare facilities. It develops and distributes its own range of nurse call hardware and software for hospitals, aged care, disability care and supported independent living. The report says the Group continues to expand into assisted independent living technologies, using synergies with its legacy Internet of Things (IoT) platform. It also says the Group is looking at other emerging technology businesses focused on IoT and healthcare.

The FY2026 report adds two items:

  • Strategic planning on enterprise-grade reporting and AI-enabled capabilities for the NuCaMS platform.

  • Evaluation of a broader "connected clinical care" offering. This would combine nurse call workflow data with complementary consumables and non-invasive monitoring inputs, to support a more proactive model of care.

The company describes this opportunity as early-stage and subject to evaluation and approvals.

The language on adjacent sectors has changed over time. The FY2024 report listed renewable energy, energy storage, new-energy vehicles and energy-saving materials as exploratory interests. By FY2026 the stated adjacencies had narrowed to IoT, healthcare and AI-related care technology. This is a meaningful sharpening of focus.

Independent characterisation

Revenue type (AUD)FY2023FY2024FY2025FY2026
Sale of goods, point in time (A$)883,160661,0282,004,3392,908,722
Projects and services, over time (A$)214,572153,704225,908185,698
Total revenue from contracts with customers (A$)1,097,732814,7322,230,2473,094,420
Goods share of customer revenue (%)80.581.189.994.0

Oakridge is, in substance, a single-business company. All of its revenue from customers comes from the Healthcare Technology segment (JCT Healthcare Pty Ltd) and all of it is earned in Australia (FY2026 Annual Financial Report, Notes 4 and 5).

The other reported segments are dormant or legacy:

Technology development: is the former Xped IoT/ADRC platform. It had no revenue and only $55,000 of consulting cost in FY2026.

Geothermal projects: comprises fully impaired Indonesian and Indian interests. Its only economic value is a contingent earn-out from KS Orka Renewables on the Sokoria project.

Unallocated: captures listed-company overheads.

Business model. JCT is a project-based systems integrator with its own product IP. It designs and specifies proprietary nurse call hardware (call points, pendants, annunciator displays, intercoms) and software (the NuCaMS platform, mobile apps, reporting and integrations). It procures and holds inventory, then delivers projects through programming, first-fix, component delivery, commissioning and installation. It also provides recurring 24/7 technical support, maintenance, networking and software development services. It sells directly and through a national network of channel partners (installers and integrators), which management has been actively expanding.

Revenue model mix. Revenue is overwhelmingly product-led and recognised at a point in time:

Source: FY2024 and FY2026 Annual Financial Reports, Note 5. The share row is an analyst calculation.

Subscription and licensing revenue are not separately reported. The legacy Bio SA royalty-linked messaging licence produced no royalties in FY2024–FY2026. The trend is notable: as revenue has scaled, the mix has moved further toward hardware. Services and projects fell to 6.0% of customer revenue in FY2026. This contrasts with listed peer Austco Healthcare, which is building a recurring software and maintenance layer (12% of its FY2026 revenue, per Austco's FY2026 results).

Value-chain position. JCT sits in the middle of the value chain. It owns product design and software IP and outsources component manufacturing. The FY2026 report refers to RTLS hardware moving into production and to "inventory in transit", implying imported components. It also handles installation, either directly or through partners. It does not own contract-manufacturing capacity.

Customer types and end-markets.

  • Public and private hospitals (acute care).

  • Residential aged care operators.

  • Disability care providers and SIL accommodation, including NDIS-funded participants and occupational-therapist-specified assistive technology.

  • Dementia care units.

  • Retirement and independent living villages.

Customers are typically facility operators, procuring directly or through builders and electrical integrators. No individual customer concentration data is disclosed.

Strategy

Stated strategic themes (paraphrased from the FY2024–FY2026 Annual Financial Reports)

  1. Product leadership and standards compliance. Advance the healthcare product suite in line with the 2024 nurse call standard.

  2. Channel-led national growth. Build new partner relationships and strengthen existing ones across aged care, disability, hospital and retirement living, while continuing direct sales.

  3. Enterprise and cloud scale. Develop NuCaMS Enterprise with multi-site reporting, single sign-on and Azure cloud integration.

  4. RTLS and assistive technology adjacency. Commercialise RTLS hardware and expand integrated SIL and assistive technology deployments.

  5. AI and connected clinical care (exploratory). Plan AI-enabled reporting for NuCaMS and evaluate a connected clinical care offering combining workflow data, consumables and non-invasive monitoring.

  6. Operational discipline. Adopt Zoho Books and inventory platforms, work toward ISO 9001:2015 and ISO 27001 readiness, and control expenses and working capital.

  7. Capital and partnerships. Monitor overheads and cash flow, strengthen the capital base and seek strategic partners. FY2024 also referred to pursuing strategic acquisitions in healthcare.

Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

InitiativeTimingStatus / targetSource
RTLS enablement of the NuCaMS core platformCompleted by Dec 2025 quarterInitial hardware production early 2026; call point and pendant work completed in FY2026Q2 FY2026 4C; FY2026 Annual Financial Report
NuCaMS Enterprise first-stage reportingFY2026Completed and demonstrated; further reporting and integration features under way toward broader deploymentFY2026 Annual Financial Report
Azure cloud integration, SSO and authenticationFY2026Cloud-based integration with Microsoft Azure validatedFY2026 Annual Financial Report
AI-enabled capability planning for NuCaMSFY2026Strategic planning stageFY2026 Annual Financial Report
Connected clinical care offeringFY2026Under evaluation; early stage; may need board or regulatory approvalFY2026 Annual Financial Report
Zoho Books and inventory systemsFY2025–FY2026Adoption progressingQ3 FY2026 4C; FY2026 Annual Financial Report
ISO 9001:2015 and ISO 27001 readinessFY2026Readiness activities ongoing; certification not yet announcedFY2026 Annual Financial Report
Marketing and digital refreshFY2026Website refresh and lead-generation work ongoing; ITAC Conference in Brisbane, May 2026FY2026 Annual Financial Report
Capital strengthening30 Jun 2026$349,996 option exercise by Montague (net $250,000 cash)FY2026 Annual Financial Report; Q4 FY2026 4C

ESG and sustainability commitments. None announced. Cost programs with targets. None with quantified targets.

Medium-term targets and guidance

The company gives no quantitative financial guidance or medium-term targets. Its only forward statement is that current channel activity and project conversion are expected to support revenue into FY2027 (FY2026 Annual Financial Report; Q4 FY2026 4C). The Q3 FY2026 update described the company as running "ahead of budget", but the budget itself was not disclosed.

Products & Services

All products sit in the Healthcare technology segment under the JCT brand. The company does not disclose pricing, unit volumes or per-product revenue. Launch years are given only where the company disclosed them.

Nurse call systems ("True IP Nurse Call")

Product / componentDescription and capabilitiesTarget customerLatest version / statusSource
NuCaMS (Nurse Call Management System)JCT's proprietary nurse call management software. It reports on call response times, call frequency, alarm types, duration, care time and compliance, with historical analysis and custom reports on request. It supports configurable clinical workflows and alerts (for example, a door opening at night).Hospitals, aged care, disability careContinuously enhanced. FY2026 work covered reporting, scalability, integration and performance.jct.com.au FAQ; FY2026 Annual Financial Report
NuCaMS EnterpriseMulti-site, enterprise-scale version of NuCaMS, deployable on physical or cloud infrastructure. In FY2026 the company completed and demonstrated first-stage enterprise reporting and validated cloud integration with Microsoft Azure. Software development covered administration, authentication, reporting and single sign-on. AI-enabled capabilities are being planned.Multi-facility operators (aged care groups, hospital networks)Development ongoing toward broader deployment milestones (FY2026).FY2026 Annual Financial Report; Q3 FY2026 4C summary
NuCaMS staff mobile appStaff nurse call app for Android and Apple iOS. Customers cite its duress functionality.Care staffMobile development ongoing (FY2026)jct.com.au; FY2026 Annual Financial Report
Call pointsBedside and room call points, including RTLS-enabled call points completed in FY2026.All care settingsRTLS call point work completed in FY2026FY2026 Annual Financial Report
Resident pendantsWearable resident call pendants, including RTLS-enabled versions completed in FY2026.Aged care, dementia, SILCompleted FY2026FY2026 Annual Financial Report
Nurse Call Intercom pointsTwo-way voice points that let staff talk to residents anywhere in the building, including via phone.Hospitals, aged careIn marketjct.com.au FAQ
LED and LCD annunciator display modulesCorridor and station displays showing active calls. Refined during FY2026.Hospitals, aged careRefined FY2026FY2026 Annual Financial Report
Wireless nurse callWireless system variants used in upgrades. Mentioned in FY2026 partner engagements.Retrofit and upgrade sitesIn marketFY2026 Annual Financial Report
Replacement serversServer hardware and arrangements supplied to installed-base customers.Installed baseReferenced in FY2026 delivery activityFY2026 Annual Financial Report

Standards alignment. The company says its product roadmap aligns with an evolving 2024 Australian nurse call standard. The FY2026 report cites it as "AS8311:2024". That exact designation could not be independently verified; it may refer to the Australian patient alarm standard series. Compliance with the current standard matters for tender eligibility.

Assistive Technology

OfferingDescriptionTarget customerNotes / source
JCT Assistive Technology suiteDescribed as award-winning. Lets residents control everyday household items with a button press, while carers receive timely alerts. Includes a staff and client app built for assistive technology use.Disability care, SIL, NDIS participants, independent livingjct.com.au. Interest from occupational therapists and NDIS participants rose significantly in FY2024 (FY2024 Annual Financial Report).
Integrated SIL deploymentsCombined nurse call, assistive technology and environmental control packages for supported living accommodation.SIL operatorsDeployments expanded in FY2026 (FY2026 Annual Financial Report; Q4 FY2026 4C)
Independent living packagesCustom packages for individuals living at home.Consumers and familiesjct.com.au

RTLS (Real-Time Location System) Positioning Technology

OfferingDescriptionStatus / source
JCT RTLSTracking of people and assets inside facilities, integrated with nurse call so call location and staff presence can be captured.RTLS enablement of the core platform completed (Q2 FY2026). Initial hardware production set for early 2026 (Jan 2026 4C). RTLS call point and pendant work completed and specification materials prepared for market (FY2026 Annual Financial Report). RTLS deployments appear in partner engagements.

CCTV, security and access control

JCT's website metadata describes "advanced CCTV & Security Solutions". GlobalData's company profile lists CCTV and access control services. No product-level detail or revenue is disclosed.

Services

ServiceDescriptionSource
24/7 technical supportNational hotline (1300 859 630) and support emailjct.com.au
Software developmentInterface development, mobile platform design, reporting products, third-party integrationsjct.com.au
Scheduled reportingAutomated statistical call reports delivered to customer executives on a schedulejct.com.au
Clinical workflow configurationCustom alerts and escalations through the NuCaMS management enginejct.com.au
NetworkingFacility data networking, regardless of which healthcare technology is installedjct.com.au
MaintenanceServicing of hospital and aged care sites across rural and metropolitan Australiajct.com.au

Legacy / dormant technology (Technology development segment)

AssetDescriptionStatus
ADRC (Auto Discovery Remote Control) IoT platformPatented technology that lets a smartphone automatically discover and control embedded devices. Components included an infrastructure platform, ADRC daemon, ADRC proxy and "One Tap" provisioning.No revenue FY2023–FY2026. Segment costs $10,000 (FY2024), $10,000 (FY2025), $55,000 (FY2026). Retained as a source of "synergies" for assisted living.
Jemsoft AI assets (acquired 2017)Computer vision and AI technologyCurrent status not publicly disclosed
Web-based messaging software (Bio SA grant, 2012–13)Messaging software licence developed with a $230,000 state grantNo royalties FY2024–FY2026; not expected to produce material royalties

Financial Narrative

Sources. FY2023–FY2024: FY2024 Annual Financial Report. FY2025–FY2026: FY2026 Annual Financial Report. FY2022: FY2024 Annual Financial Report (five-year table, opening balances), with FY2022 customer revenue taken from TipRanks (an aggregator, labelled accordingly). Blank cells mean not publicly disclosed in the sources available.

Margins and growth (analyst calculations)

Revenue CAGR. Customer revenue grew at about 58% a year over FY2022–FY2026, from $496,860 to $3,094,420. The FY2022 base is from an aggregator.

Commentary.

Revenue inflection: Revenue roughly tripled between FY2024 and FY2026. Management attributes this to increased business development and channel-partner expansion (FY2025 and FY2026 Appendix 4E). The FY2024 dip (−25.8%) followed a lumpy FY2023. This volatility is typical of project-based nurse call revenue at small scale.

Gross margin compression, then recovery: Gross margin fell from 63.7% (FY2023) to 50.1% (FY2025), then recovered to 54.7% (FY2026). The decline is consistent with a mix shift toward hardware supply through channel partners, who keep installation margin, and with competitive pricing to win volume. The FY2026 recovery suggests some operating leverage in procurement. JCT's gross margin is close to Austco Healthcare's FY2026 gross margin of 53.4%.

Profit quality: The FY2026 statutory profit of $109,171 is less than the $349,527 R&D tax incentive recognised. Without the incentive, the group would have lost about $240,000. Every year from FY2023 to FY2026 shows an underlying loss. Still, the underlying loss has narrowed by about $950,000 from FY2024 to FY2026, which is the key positive trend.

Costs: Employee and contracting costs rose 30% in FY2026 to $939,522, below the 39% rise in customer revenue. Consulting fees fell from $180,000 to $60,000. Professional and legal fees remain elevated at $137,160 for a company of this size.

Balance sheet (A$, 30 June)

Short- and long-term debt split.

Bank debt: none. The Group had no undrawn facilities at 30 June 2026.

Bio SA loan ($32,548): shown as current on the balance sheet but as 1–5 years in the liquidity maturity table, a minor internal inconsistency.

Leases: $62,906, all due within 12 months at 30 June 2026. The corporate office lease expires 12 March 2027 and the JCT office lease expires 14 November 2026.

Contingent liability: the Bio SA loan balance of $288,109 is not recognised. It is payable only if JCT becomes insolvent or leaves South Australia.

Commentary.

Balance sheet scale: The balance sheet is tiny but unlevered. Cash fell from $1.73 million (FY2022) to $0.47 million (FY2025) before recovering to $0.64 million (FY2026). The recovery came from positive operating cash flow and a $250,000 net cash option exercise.

Inventory build: Inventory more than doubled in FY2026 to $795,724, and $102,827 of prepaid inventory sat in prepayments. This reflects management's stated build ahead of anticipated demand and RTLS hardware production. It ties up most of working capital.

Inventory as audit risk: Inventory valuation was the Key Audit Matter in both FY2024 and FY2026. The obsolescence provision was cut by $250,000 in FY2025, which was booked as a reversal through profit. FY2026 gross inventory was $986,513 against a provision of $190,789.

Tax losses: Unrecognised tax losses (tax-effected at 25%) were $10.42 million at 30 June 2026. That implies about $41.7 million of gross carried-forward losses. These are a latent asset whose usability depends on passing the continuity-of-ownership or similar-business tests.

Cash flow (A$)

Commentary.

First positive operating cash flow: FY2026 was the first year in the series with positive operating cash flow ($127,028). It was helped by $349,527 of R&D refunds; without the refund, operating cash flow would have been about −$222,000.

Lease-adjusted free cash flow: After lease principal, free cash flow remained negative at −$81,298.

Option exercise mechanics: Of the $349,996 recorded for Montague's option exercise, $99,996 was "expenses converted to shares". Net new cash was $250,000. During the year the Group drew and repaid $250,000 of borrowings, consistent with the $215,000 interest-free director-related advance disclosed at the half year. Investors should note the related-party funding dependence.

Ratios (analyst calculations; averages use opening and closing balances)

Commentary.

Returns: Returns turned positive in FY2026. Small denominators magnify the percentages: a ROIC of 15.3% on roughly $0.73 million of average invested capital means little in absolute terms.

Working capital: Working capital is the critical efficiency metric. The cash conversion cycle improved sharply in FY2025 (95.5 days) as inventory turned, then lengthened to 166.6 days in FY2026 because of the deliberate inventory build.

Leverage: Leverage is negligible and the Group is net cash. Net debt to EBITDA of −2.31x indicates a net cash position, so it is not a meaningful leverage measure.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryOwnershipRole

Oakridge International Limited

Australia

Listed parent

Holding company, corporate costs

JCT Healthcare Pty Ltd

Australia

100%

Operating company: nurse call, assistive technology, RTLS

Oakridge Healthcare Pty Ltd

Australia

100%

Holding/intermediate (activities not separately disclosed)

Oakridge Asia Holdings Pty Ltd

Australia

100%

Legacy holding vehicle for geothermal interests (activities not separately disclosed)

Osiris Energy Pty Ltd

Australia

100%

Legacy energy vehicle; converted from public to proprietary company in FY2023

Revenue by Segment (AUD)

SegmentFY2023FY2024FY2025FY2026

Healthcare technology revenue (AUD)

1,247,7641,170,0232,433,0743,357,231

Technology development revenue (AUD)

0000

Geothermal projects revenue (AUD)

0000

Unallocated revenue (AUD)

13,2387,00626688,777

Total revenue and other income (AUD)

1,261,0021,177,0292,433,3403,446,008

Revenue by Segment (AUD) — Healthcare technology PBT

SegmentFY2023FY2024FY2025FY2026

Healthcare technology PBT (AUD)

428,983-97,172563,822671,218

Technology development PBT (AUD)

0-10,000-10,000-55,000

Geothermal projects PBT (AUD)

-1,856145,07700

Unallocated PBT (AUD)

-543,239-799,153-761,715-507,047

Group PBT (AUD)

-116,112-761,248-207,627109,171

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2023FY2024FY2025FY2026

Healthcare technology PBT margin on segment revenue (%)

34.4-8.323.220.0

Healthcare technology segment revenue YoY growth (%)

—-6.2108.038.0

Healthcare technology share of group revenue (%)

99.099.4100.097.4

Healthcare technology PBT excluding R&D incentive and one-offs (AUD)

-90,192-381,128110,995408,856

Income Statement (AUD) and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from contracts with customers (AUD)

496,8601,097,732814,7322,230,2473,094,420

R&D tax concession recognised (AUD)

—149,741176,384202,827349,527

Total revenue and other income (AUD)

—1,261,0021,177,0292,433,3403,446,008

Cost of sales (AUD)

—398,284333,0031,112,1011,401,242

Gross profit on customer revenue (A$, derived)

—699,448481,7291,118,1461,693,178

Employee and contracting expenses (AUD)

—576,058632,834724,267939,522

Directors' remuneration (AUD)

—235,992244,992247,992247,992

Operating income / EBIT excl. interest income (A$, derived)

—-101,740-725,952-200,119111,551

EBITDA (A$, derived)

—-67,345-619,848-85,522235,068

Finance costs (AUD)

—27,79542,3027,7744,441

Profit before tax (AUD)

—-116,112-761,248-207,627109,171

Income tax benefit (AUD)

—0078,8320

Net profit attributable to owners (AUD)

-531,030-116,112-761,248-128,795109,171

Underlying PBT excl. R&D incentive and one-offs (A$, derived)

—-635,287-1,191,392-660,454-240,356

Basic and diluted EPS, recalculated (A cents)

-3.09-0.68-4.31-0.480.40

Dividends per share (A cents)

00000

Margin Analysis (%)

MetricFY2023FY2024FY2025FY2026

Customer revenue YoY growth (%)

120.9-25.8173.738.7

Total revenue YoY growth (%)

—-6.7106.741.6

Gross margin on customer revenue (%)

63.759.150.154.7

EBIT margin on total revenue (%)

-8.1-61.7-8.23.2

EBITDA margin on total revenue (%)

-5.3-52.7-3.56.8

Net margin on total revenue (%)

-9.2-64.7-5.33.2

R&D incentive as share of total revenue (%)

11.915.08.310.1

Balance Sheet (AUD) and Share Count (number)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD)

—1,985,1231,807,7911,606,0972,123,849

Cash and cash equivalents (AUD)

1,725,2731,091,900961,575468,939637,641

Term deposits securing lease guarantees (AUD)

—48,44864,10061,94861,948

Trade and other receivables (AUD)

—100,890170,991138,878284,683

Inventory, net (AUD)

—441,242305,688380,757795,724

Inventory obsolescence provision (AUD)

—440,789440,789190,789190,789

Plant and equipment (AUD)

—40,57841,35464,873144,085

Right-of-use assets (AUD)

—253,530258,462157,57056,679

Goodwill and intangibles (AUD)

—0000

Total current liabilities (AUD)

—546,538586,895625,406737,693

Borrowings, Bio SA royalty loan (AUD)

—32,54832,54832,54832,548

Lease liabilities (AUD)

—256,227268,500169,39362,906

Total debt incl. leases (AUD)

—288,775301,048201,94195,454

Net cash, cash minus debt incl. leases (AUD)

—803,125660,527266,998542,187

Total liabilities (AUD)

—755,201776,750703,851762,436

Total equity (AUD)

1,346,0341,229,9221,031,041902,2461,361,413

Contributed equity (AUD)

28,799,41128,799,41129,329,69029,329,69029,679,686

Accumulated losses (AUD)

27,453,37727,569,48928,330,73728,459,53228,350,361

Working capital (A$, derived)

—1,144,477921,080758,2481,185,392

Shares on issue (number)

17,195,67917,195,67926,997,90826,997,90831,997,851

Cash Flow (AUD)

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD)

—1,090,606568,2472,254,2532,958,569

R&D incentives and grants received (AUD)

—281,242176,384202,827349,527

Payments to suppliers and employees (AUD)

—1,796,7351,272,3182,804,4923,178,688

Operating cash flow (AUD)

—-414,602-530,672-358,457127,028

Capital expenditure, plant and equipment (AUD)

—28,46116,68537,224101,838

Free cash flow, OCF minus capex (A$, derived)

—-443,063-547,357-395,68125,190

Lease principal paid (AUD)

—20,35282,96899,107106,488

FCF after lease principal (A$, derived)

—-463,415-630,325-494,788-81,298

Equity issued, gross (AUD)

—0500,0000349,996

Dividends paid (AUD)

00000

Share buybacks (AUD)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

Return on equity (%)

-9.0-67.3-13.39.6

Return on assets (%)

—-40.1-7.55.9

ROIC, EBIT over equity plus debt minus cash (%)

—-182.1-39.815.3

Current ratio (x)

3.092.572.212.61

Debt to equity incl. leases (x)

0.230.290.220.07

Net debt to EBITDA (x)

———-2.31

Interest coverage, EBIT over finance costs (x)

-3.66-17.16-25.7425.12

Asset turnover, customer revenue over average assets (x)

—0.431.311.66

Days sales outstanding, year-end (days)

30.670.522.733.6

Days inventory outstanding, year-end (days)

404.4335.1125.0207.3

Days payables outstanding, year-end (days)

156.7134.052.274.3

Cash conversion cycle (days)

278.3271.695.5166.6

Revenue by Region (AUD) and Region Margins & Growth (%)

RegionFY2023FY2024FY2025FY2026

Australia customer revenue (AUD)

1,097,732814,7322,230,2473,094,420

Rest of world customer revenue (AUD)

0000

Australia YoY growth (%)

—-25.8173.738.7

Australia share of customer revenue (%)

100100100100

Share Price and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.0730.0720.0710.0600.072

Shares on issue at 30 June (millions)

17.2017.2027.0027.0032.00

Market capitalisation at 30 June (AUD Mn)

1.261.241.921.622.30

Return period (to 30 Jun 2026)

Return period (to 30 Jun 2026)Return (%)Basis

1-year

20.0

$0.060 to $0.072

3-year

0.0

$0.072 to $0.072

5-year

-64.0

$0.001 pre-consolidation at 30 Jun 2021, equal to $0.20 after the 200:1 consolidation, to $0.072

Valuation Multiples

MultipleOakridgeNote

Market cap (AUD Mn)

2.05

31,997,851 shares

Enterprise value (AUD Mn)

About 1.51

Market cap − cash $0.64m + debt incl. leases $0.10m

P/E (x)

About 18.8

On statutory PAT of $109,171. Kalkine shows a trailing P/E of 7.10 on a different TTM basis; the discrepancy is noted.

EV/EBITDA (x)

About 6.4

On derived EBITDA of $235,068, which includes the R&D incentive

EV/Sales (x)

About 0.49

On customer revenue

P/B (x)

About 1.5

Equity $1.36m

Price/NTA (x)

About 1.6

NTA 4.08 cents per share

Analyst Conclusions

Management guidance

There is no quantitative guidance. Management expects current channel activity, qualified opportunities and project conversion to support revenue into FY2027. It will continue to monitor overheads and cash flow, strengthen the capital base, seek strategic partners and assess complementary product, technology and AI opportunities (FY2026 Annual Financial Report; Q4 FY2026 4C).

Consensus expectations

None. The company has no analyst coverage.

Bull case

  1. Operating leverage is visible. Customer revenue rose 39% in FY2026 while the unallocated cost base fell 33% (to $507,047). If JCT grows another 25–35% at a gross margin of 54–55%, the company could reach underlying profitability excluding R&D incentives within one to two years. That would release value from the $10.42 million tax-effected loss pool.

  2. RTLS and NuCaMS Enterprise raise deal value and recurrence. Completed RTLS call points and pendants, validated Azure integration and multi-site reporting give the installed base a clear upgrade path. This could help reverse the fall in the services share toward Austco-style recurring revenue.

  3. Strategic value floor. With an enterprise value of about $1.5 million, Oakridge trades near or below what a scale consolidator just paid for a South Australian nurse call peer ($2.88 million). A controlling shareholder who has kept investing equity is well placed to negotiate a sale or merger.

Bear case

  1. Low-quality earnings. FY2026 profit is entirely the R&D incentive ($349,527 against PBT of $109,171). The underlying business still loses about $240,000 a year after head-office costs, and free cash flow after leases was −$81,298 even in a record year.

  2. Squeezed by consolidation. Austco has 30 times the revenue, A$16.3 million of cash and an active acquisition program in Australia, including OAK's home state. This threatens OAK's channel partners, tender competitiveness and pricing power.

  3. Governance and minority-holder risk. A CEO with a 52.81% stake, a combined Chair and CEO role, a three-person board, related-party consulting and funding arrangements, and a six-year unquantified Teko contingent liability. Minority holders have little influence, and the register is so illiquid that most holders own unmarketable parcels.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
By 31 Oct 2026Q1 FY2027 Appendix 4C: customer receipts against the $770,000 Q4 FY2026 run-rate, and inventory drawdown
Nov 20262026 AGM: board composition, remuneration resolutions, any capital-raising mandates
13 Nov 2026Expiry of 306,480 employee options ($0.10)
14 Nov 2026JCT office lease expiry: renewal terms, and whether JCT stays in South Australia (Bio SA contingency trigger)
19 Dec 2026Expiry of 599,970 Unerkov-associated options ($0.10)
Late Jan 2027Q2 FY2027 4C: RTLS hardware revenue contribution
Feb 2027H1 FY2027 interim results: underlying profitability excluding R&D incentive
12 Mar 2027Corporate office lease expiry: opportunity to cut overhead
OngoingISO 27001 / ISO 9001 certification announcements; any connected clinical care or AI transaction; KS Orka further NOIDs; Teko SPA resolution; Austco consolidation moves; FY2026 R&D incentive claim size (received in FY2027)

Analyst verdict

Oakridge International is a holding company that has finally become an operating company. After a decade of reinventions — geothermal developer, IoT platform, AI acquirer — almost all of the residual value now sits in JCT Healthcare, a two-decade-old Adelaide nurse call and assistive technology specialist. On the evidence of the FY2025 and FY2026 accounts, JCT is gaining commercial traction. Customer revenue nearly quadrupled between FY2024 and FY2026 to $3.09 million. Gross margins of about 55% match the regional market leader. The operating segment earns a genuine underlying profit before head-office costs.

The problem is everything above the operating line. A listed-company overhead of roughly half a million dollars, plus a profit that rests entirely on R&D tax refunds, means FY2026's first full-year profit since FY2021 is a milestone of trajectory, not of quality. Working capital is stretched by a doubled inventory balance, and the company has twice in three years turned to its controlling shareholder for funding. Governance is concentrated to a degree most institutional investors would not accept.

Strategically, the clock is ticking. Austco Healthcare is consolidating the Australian market with a strong balance sheet, and its August 2026 purchase of a South Australian nurse call business suggests small independents are more valuable inside a platform than alone. Organic progress on RTLS and NuCaMS Enterprise is real but early, and the "connected clinical care" and AI ideas are not yet business plans.

Our assessment is that Oakridge is a speculative, illiquid special situation. Its fundamentals are improving and its valuation is low (EV of about $1.5 million, about 0.5 times sales). Upside is most likely to come from a strategic transaction led by the controlling shareholder, or from two to three more quarters showing profitability excluding R&D incentives. Minority investors face significant liquidity, governance and execution risk and should size any exposure accordingly.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationAgeFY2026 total remuneration (AUD)

Con Unerkov

Executive Chairman and CEO (also described as interim CFO by data providers); member of the Nomination and Remuneration Committee

Non-executive Chairman 31 Dec 2019; CEO 3 Feb 2021

More than 25 years as an executive and CEO in private and public companies, focused on structuring, M&A and corporate finance. The FY2026 report describes him as Chairman and CEO of Integrated Media Technology Limited (NASDAQ: IMTE). The FY2024 report described him as a former chairman of IMTE and chairman of a clean-energy charging company; this inconsistency is noted.

—

About 57 (born 1969, per Yahoo Finance)

199,992

Peter Whelan

Independent non-executive director; Audit Committee Chair; member of the Nomination and Remuneration Committee

29 Jan 2021

Chartered Accountant with more than 50 years' experience. Former Managing Partner and Chairman of Partners at a mid-tier South Australian accounting firm (corporate advisory and audit). Extensive auditing in aged care and retirement living. Charity board and finance committee member.

——24,000

Wally Pastuch

Non-executive director; Nomination and Remuneration Committee Chair; Audit Committee member

3 Mar 2025

More than 40 years across the automotive, insurance and IT industries. Implemented inventory systems at Ford Australia, was Regional Manager VIC/TAS at Mitsubishi Motors Australia, and developed insurance products at an IAG affiliate.

——24,000

Julie Edwards

Company Secretary

—

Accounting and finance management experience. B.Com, CPA Australia member, CPA Public Practice Certificate, registered Tax Agent.

B.Com

—

Not disclosed (not KMP)

John Schultz

Founder and Head of Engineering (per Yahoo Finance; Xped co-founder)

—

Xped co-founder

—

About 61 (born 1965)

—

Christopher Wood

Founder and CTO (per Yahoo Finance; Xped co-founder)

—

Xped co-founder

—

About 64 (born 1962)

136,970 (per Yahoo Finance; year unspecified)

“—” = not publicly disclosed.

Executive Leadership Team

NameFY2023FY2024FY2025FY2026

Con Unerkov total remuneration (AUD)

201,867221,231199,992199,992

Peter Whelan fees (AUD)

18,00022,50024,00024,000

Elvis Diao fees (AUD)

18,00022,50016,0000

Wally Pastuch fees (AUD)

008,00024,000

Total KMP compensation (AUD)

237,867266,231247,992247,992

Board & Management Changes

DateChangeContext

31 Dec 2019

Con Unerkov appointed non-executive Chairman

Linked to the Teko International placement

24 Apr 2020

Elvis Diao appointed NED

Greater China investor-relations background

29 Jan 2021

Peter Whelan appointed NED

Brought audit and aged-care sector expertise

3 Feb 2021

Unerkov becomes CEO, remaining Chairman

Restructuring before the Oakridge rebrand

FY2025 (before Mar 2025)

Elvis Diao departs

Received $16,000 in FY2025, consistent with about eight months of service

3 Mar 2025

Wally Pastuch appointed NED

Systems and inventory management background

Major Shareholders

RankHolderShares% of issued capital
1

Montague Capital Pty Ltd (Unerkov-associated)

16,898,43952.81
2

Teko International Limited

3,125,0009.77
3

Aliton Pty Ltd (Bell Family Super Fund A/C)

1,674,3095.23
4

Heuresy Labs LLC

1,000,0003.13
5

Mr Gabriel Govinda

719,9442.25
6

JK Group Australia Pty Ltd (JK Family A/C)

701,4412.19
7

Aerobotics Pty Ltd

370,0001.16
8

BNP Paribas Nominees Pty Ltd (Clearstream)

347,9211.09
9

Alanticx Technologies Pty Ltd (Alanticx A/C)

222,0840.69
10

Aliton Pty Ltd

220,0130.69

Competitive Landscape

Key Competitors

CompetitorOwnership / listingRelevant offeringScale / revenuePositioning vs OAKSource

Austco Healthcare (Tacera, Pulse Mobile)

ASX: AHC

IP nurse call, clinical workflow, RTLS, mobile

FY2026 revenue A$94.2m; EBITDA A$14.9m; NPAT A$9.0m; more than 5,000 facilities in 60+ countries

About 30 times OAK's revenue; acquisitive; debt-free with A$16.3m cash

Austco FY2026 results

Ascom

SIX Swiss Exchange

Nurse call, mobility, clinical alarm management; acquired GE Healthcare's nurse call unit

—

Global hospital-focused player

Mobile World Live (historical)

Rauland (AMETEK)

NYSE: AME subsidiary

Responder nurse call

Not disclosed separately

Mainly US hospitals; limited Australian aged-care overlap

General industry knowledge

Baxter / Hillrom (Voalte, NaviCare)

NYSE: BAX

Nurse call, care communications

Not disclosed separately

Acute hospital focus

General industry knowledge

Stryker (Vocera)

NYSE: SYK

Clinical communications

Not disclosed separately

Hospital mobility and communications

General industry knowledge

Advance Care

Private (Australia, founded 2000)

Advance Care nurse call system; branch and reseller network

—

Closest like-for-like domestic aged care competitor; claims many major acute and aged care operators

MedicalSearch listing

Medical Communications Systems Pty Ltd

Acquired by Austco on 13 Aug 2026 (South Australia)

Nurse call

Acquisition price about A$2.88m

Former local peer, now part of the scale player

Austco FY2026 results

Teknocorp, Amentco, G&S Technologies

Acquired by Austco

Nurse call and security integration

—

Consolidated into Austco

Austco FY2026 results

Tunstall

Private (UK)

Telecare, aged care alarms

—

Independent living and telecare overlap

General industry knowledge

Critical Alert Systems (with Intego)

Private (US)

Nurse call and workflow

—

US-focused

PRNewswire, 2012

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricOakridge (FY2026)Austco Healthcare (FY2026)

Revenue (AUD Mn)

3.09 (customer); 3.45 (incl. other income)

94.2

Revenue growth (%)

38.7 (customer)

15.8

Gross margin (%)

54.753.4

EBITDA margin (%)

6.8 (incl. R&D incentive)

15.8

Net margin (%)

3.2

9.6 (derived: 9.0/94.2)

Recurring software and maintenance share (%)

About 6 (projects and services, over time)

12

Cash (AUD Mn)

0.6416.3

Recent Developments

Items such as product launches with named customers, contract wins with values, litigation and layoffs were not publicly disclosed. The register above lists every identifiable development in the period.

Company Snapshot

2006

Founded

Adelaide, Australia

Headquarters

SWOT Analysis

Strengths

  • Revenue momentum. Customer revenue grew 174% in FY2025 and 39% in FY2026, from $814,732 to $3,094,420 in two years (FY2024 and FY2026 Annual Financial Reports).
  • Healthy product margins. Gross margin of 54.7% in FY2026, above Austco's 53.4%, despite far smaller purchasing scale (derived from Note 4; Austco FY2026).
  • Operating unit profitable before head-office costs. Healthcare technology segment PBT of $671,218 in FY2026; about $409,000 excluding R&D incentives (FY2026 Annual Financial Report, Note 4).
  • Unlevered balance sheet. No bank debt; net cash of $542,187 including leases; current ratio 2.61 (30 Jun 2026).
  • Integrated proprietary suite. NuCaMS, NuCaMS Enterprise, mobile apps, RTLS call points and pendants, assistive technology and annunciators, with Azure integration validated (FY2026 Annual Financial Report).
  • Committed major shareholder. Montague Capital put in $500,000 in FY2024 and $349,996 in FY2026, and a director-related entity advanced $215,000 interest-free in H1 FY2026, giving funding support in stress periods.

Weaknesses

  • Profit depends on R&D incentives. FY2026 PBT of $109,171 is less than the $349,527 R&D incentive; underlying PBT was about −$240,000 (FY2026 Annual Financial Report).
  • Heavy listed-company overhead. Unallocated costs were $507,047 in FY2026, including directors' fees of $247,992 (8% of customer revenue).
  • Low recurring revenue. Over-time services were only 6.0% of customer revenue in FY2026, down from 19.5% in FY2023 (Note 5).
  • Working-capital intensity. Inventory days of 207 and a cash conversion cycle of 167 days in FY2026. Inventory valuation is the Key Audit Matter (FY2026 auditor's report).
  • Governance concentration. Combined Chair and CEO, a three-person board, a two-member audit committee, and a remuneration committee that held no meetings in FY2024–FY2026.
  • Single-country, single-segment exposure. 100% of customer revenue from Australia (Note 5).

Opportunities

  • RTLS commercialisation. Hardware production began in 2026, giving an upsell into the installed base (Q2 FY2026 4C).
  • Enterprise and multi-site deployments. NuCaMS Enterprise with SSO and cloud could lift deal sizes and add recurring software revenue (FY2026 Annual Financial Report).
  • AI-enabled analytics and connected clinical care. Could differentiate the product and add data and consumable revenue streams (FY2026 Annual Financial Report; early stage).
  • Tax-loss shield. $10.42 million of tax-effected unrecognised losses could shelter future profits, subject to loss-continuity tests (FY2026 Annual Financial Report, Note 7).
  • Sector consolidation. Austco paid about $2.88 million for a South Australian nurse call business in August 2026, while OAK's market capitalisation is about $2.05 million. This creates potential for a strategic sale or merger (Austco FY2026 results).
  • KS Orka earn-out. Up to about US$695,000 of the original US$947,368 cap remains theoretically receivable (cap less US$252,703 received), carried at nil (FY2026 Annual Financial Report, Note 4).

Threats

  • Competitor scale. Austco has 30 times the revenue and A$16.3m of cash, and is acquiring Australian integrators (Austco FY2026 results).
  • Channel disintermediation. OAK relies on partners who may be acquired by competitors or switch vendors (FY2026 Annual Financial Report on partner reliance).
  • R&D incentive policy risk. Changes to the Australian R&D Tax Incentive would directly cut reported profit and cash (10.1% of FY2026 total revenue).
  • Contingent liabilities. Unquantified potential SPA-breach claim by Teko International; $288,109 Bio SA contingent loan (FY2026 Annual Financial Report, Notes 24–25).
  • Liquidity and delisting-style risks. 461 of 651 holders below a marketable parcel; very thin trading (average volume about 14,458 shares, TipRanks, Aug 2025).
  • Imported component and foreign exchange costs. Unhedged foreign exchange exposure on supplier payments (FY2026 foreign exchange loss $14,110; no hedging per Note 3).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Mar 2025Wally Pastuch appointed NED, replacing Elvis Diao FY2026 Annual Financial ReportBoard refresh; adds systems and inventory skills
Apr 2025 (Q3 FY2025 4C)Quarterly cash flow report filed StockLight announcement list–
Jul 2025 (Q4 FY2025 4C)Quarterly cash flow report filed InvestSMART (flagged)Routine. An aggregator's AI summary of this release referred to "battery technology" and the March 2024 quarter; this conflicts with filings and is disregarded as an aggregator error.
22 Aug 2025FY2025 Appendix 4E and Annual ReportRevenue +107% to $2.43m; loss −83% to $128,795; $250,000 inventory provision reversal; $78,832 tax benefit relating to prior years
Aug 2025Market capitalisation about A$1.84m TipRanksIllustrates micro-cap scale
Oct 2025Notice of 2025 AGM published oakridgeint.comGovernance cycle
31 Oct 2025Q1 FY2026 Appendix 4C StockLight–
Nov 20252025 AGM held Inferred from AGM notice–
H1 FY2026$215,000 interest-free short-term advance from a director-associated entity H1 FY2026 report summaryRelated-party liquidity support
30 Jan 2026Q2 FY2026 4C: strong quarter; RTLS enablement complete; hardware production early 2026; operating cash flow down on inventory investment; exploring funding options InvestSMART summaryRTLS milestone; signals working-capital strain
11 Feb 2026Half-year report: PAT $172,239 (vs loss $126,968); revenue +61.9% to $1.79m; total assets $2.11m; net assets $1.07m InvestSMART summary of H1 FY2026 reportFirst profitable half in several years
30 Apr 2026Q3 FY2026 4C: customer receipts $988,000; positive cash flow helped by government (R&D) receipts; "ahead of budget"; RTLS and NuCaMS Enterprise progress; internal systems upgrades InvestSMART summary; StockLightStrongest disclosed receipts quarter; share price rose about 17–20% on release
May 2026ITAC Conference, Brisbane, with a Queensland partner FY2026 Annual Financial ReportAssistive technology market presence
FY2026Austco Healthcare acquisitions in Australia (G&S Technologies full-year effect; Teknocorp, Amentco) Austco FY2026 resultsA competitor consolidating the ANZ market
30 Jun 2026Montague exercises 4,999,943 options at $0.07; 2,142,914 options lapse FY2026 Annual Financial ReportControl stake rises to 52.81%; $349,996 equity
31 Jul 2026Q4 FY2026 4C: receipts $770,000 for the quarter and $2.962m for FY2026 (vs $2.458m); management expects channel activity to drive FY2027 revenue Kalkine Media summaryConfirms full-year growth
4 Aug 2026Register snapshot: 651 holders; top 20 own 84.31% FY2026 Annual Financial ReportLiquidity and float constraints
13 Aug 2026Austco acquires Medical Communications Systems Pty Ltd (South Australia) for about $2.88m Austco FY2026 resultsCompetitive threat in the home market; private-market valuation reference
24 Aug 2026FY2026 Appendix 4E and Annual Report: revenue +42% to $3.45m; PAT $109,171; NTA 4.08 cents per share; inventory valuation remains the Key Audit MatterFirst full-year profit since FY2021
24 Aug 2026FY2026 Corporate Governance Statement published oakridgeint.comAnnual governance disclosure
Late Aug 2026Share price about A$0.064, down about 12% on the day after results InvestSMARTMarket sceptical of the low-quality profit
Aug 2026jct.com.au refreshed (new logo assets dated 2026-08) jct.com.au metadataMarketing refresh delivered

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement (AUD): Total revenue and other income to Directors' remuneration: Total revenue and other income rose from AUD 1,261,002 in FY2023 to AUD 3,446,008 in FY2026.
Oakridge International Limited — Income Statement (AUD): Total revenue and other income to Directors' remuneration
Series (AUD)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income—1,261,0021,177,0292,433,3403,446,008
Revenue from contracts with customers496,8601,097,732814,7322,230,2473,094,420
R&D tax concession recognised—149,741176,384202,827349,527
Cost of sales—398,284333,0031,112,1011,401,242
Gross profit on customer revenue—699,448481,7291,118,1461,693,178
Employee and contracting expenses—576,058632,834724,267939,522
Directors' remuneration—235,992244,992247,992247,992

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Oakridge International Limited, Appendix 4E and Annual Financial Report for the year ended 30 June 2026 (released 24 Aug 2026) (bulletin.webull.com)
  2. Oakridge International Limited, Annual Financial Report for the year ended 30 June 2024 (released 29 Aug 2024) (announcements.asx.com.au)
  3. Oakridge International Limited, Appendix 4E FY2025 (22 Aug 2025) (announcements.asx.com.au)
  4. Oakridge International Limited, Annual Financial Report FY2025 (announcements.asx.com.au)
  5. Oakridge International Limited, Appendix 4E and Annual Financial Report FY2023 (announcements.asx.com.au)
  6. Oakridge International Limited, Appendix 4D half-year to 31 Dec 2025 (bulletin.webull.com)
  7. Oakridge International Limited, Appendix 4D half-year to 31 Dec 2024 (announcements.asx.com.au)
  8. InvestSMART summaries of OAK ASX releases (Q2 FY2026 4C, H1 FY2026, Q3 FY2026 4C, FY2026 4E): ; /2487806 ; /2519771 ; /2564656 (investsmart.com.au)
  9. Kalkine Media, Q4 FY2026 4C summary (31 Jul 2026) (kalkinemedia.com)
  10. FilingReader, FY2026 results summary (filingreader.com)
  11. Oakridge corporate website · JCT Healthcare website
  12. Market Index OAK profile (marketindex.com.au)
  13. Morningstar OAK profile (morningstar.com.au)
  14. Simply Wall St OAK profile (simplywall.st)
  15. Yahoo Finance OAK.AX profile (au.finance.yahoo.com)
  16. TipRanks OAK income statement (tipranks.com)
  17. Kalkine OAK data page (kalkinemedia.com)
  18. StockLight OAK announcements and annual reports (stocklight.com)
  19. InvestSMART Xped (XPE) announcement list (investsmart.com.au)
  20. GlobalData company profile (globaldata.com)
  21. ThinkGeoEnergy, Panax renamed Raya Group (May 2013) (thinkgeoenergy.com)
  22. ThinkGeoEnergy, Sokoria sale to KS Orka (thinkgeoenergy.com)
  23. Petromindo, Panax changed into Raya Group (Apr 2013) (petromindo.com)
  24. Lawyers Weekly, Xped acquires Jackson Care Technologies (21 Jul 2016) (lawyersweekly.com.au)
  25. Business News Australia, Xped acquires Jemsoft (businessnewsaustralia.com)
  26. Wikipedia, Xped (en.wikipedia.org)
  27. CB Insights, Xped (cbinsights.com)
  28. vLex, Xped–Arcadyan MoU summary (au.vlex.com)
  29. MarketScreener, Athanasios Lekkas profile (in.marketscreener.com)
  30. Austco Healthcare FY2026 results (FilingReader; SmallCaps; Quartr) · smallcaps.com.au · quartr.com
  31. Austco Healthcare 1H FY2026 ASX release (announcements.asx.com.au)
  32. MedicalSearch, Advance Care nurse call (medicalsearch.com.au)
  33. SEC EDGAR, Oakridge International Corp (unrelated Nevada entity, CIK 0001439724) (sec.gov)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.